Erratum to "Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses" [Antiviral Res. 71 (2006) 322-334] (DOI:10.1016/j.antiviral.2006.03.012);Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 322-334

  Schinazi, Raymond F ^a,b   Hernandez Santiago, Brenda I ^a,b   Hurwitz, Selwyn J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Antiviral agents; HIV; Nucleoside analogs; Pharmacology

Indexed keywords

1 (2 HYDROXYMETHYL 1,3 DIOXOLAN 4 YL)THYMINE; 2' DEOXY 3' OXA 4' THIOCYTIDINE; 9 (BETA DEXTRO 1,3 DIOXOLAN 4 YL) 2 AMINOPURINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMDOXOVIR; AMODOXOVIR; ANTIVIRUS AGENT; AVX 754; BETA DEXTRO 2',3' DIDEHYDRO 2',3' DIDEOXY 5 FLUOROCYTIDINE; BETA DEXTRO 2,6 DIAMINOPURINE DIOXOLANE; CARBOVIR; DEXELVUCITABINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NUCLEOSIDE ANALOG; PROBENECID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; SULFAMETHOXAZOLE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ANEMIA; ANTIVIRAL ACTIVITY; BONE MARROW TOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION; SHORT SURVEY; TOXICITY; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33747100570     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.09.003     Document Type: Erratum

References (155)

1. Acosta E., Henry K., Baken L., Page L., and Fletcher C. Indinavir concentrations and antiviral effect. Pharmacotherapy 19 (1999) 708-712
2. Adams J., Sawyer J., and Shiveley L. Intracellular SPD754 triphosphate pharmacokinetics following administration of SPD754 capsules. Proceedings of the 11th Conference on retroviruses and oppotunistic infections. Moscone West, San Francisco, CA (2004)
3. Anderson P.L., Kakuda T.N., and Liechtenstein K.A. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38 (2004) 743-753
4. Arner E.S., Valentin A., and Eriksson S. Thymidine and 3′-azido-3′-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J. Biol. Chem. 267 (1992) 10968-10975
5. Back D.J., Burger D.M., Flexner C.W., and Gerber J.G. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J. Acquir. Immune Defic. Syndr. 39 1 (2005) S1-S23
6. Bang L.M., and Scott L.J. Emtricitabine. An antiretroviral agent for HIV infection. Drugs 63 (2003) 2413-2424
7. Barbier O., Turgeon D., Girard C., Green M.D., Tephly T.R., Hum D.W., and Belanger A. 3′-Azido-3′-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28 (2000) 497-502
8. Barditch-Crovo P., Deeks S.G., Collier A., Safrin S., Coakley D.F., Miller M., Kearney B.P., Coleman R.L., Lamy P.D., Kahn J.O., McGowan I., and Lietman P.S. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45 (2001) 2733-2739
9. Barreiro P., Garcia-Benayas T., Rendon A., Rodriguez-Novoa S., and Soriano V. Combinations of nucleoside/nucleotide analogues for HIV. AIDS Rev. 6 (2004) 234-243
10. Barry M.G., Khoo S.H., Veal G.J., Hoggard P.G., Gibbons S.E., Wilkins E.G., Williams O., Breckenridge A.M., and Back D.J. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10 (1996) 1361-1367
11. Bethell R., Adams J., De Mys J., Lippens J., Richard A., Ren C., Collins P., Struthers-Semple C., Holdich T., and Sawyer J. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004)
12. Bethell R., Collins P., de Muys J., Lippens J., Hamelin B., Richard A., and Sawyer J. An in vitro evaluation of the intracellular anabolism of SPD754 and FTC alone and in combination. Proceedings of the 15th International AIDS Conference. Bangkok, Thailand (2004)
13. Bethell R.C., Lie Y.S., and Parkin N.T. In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir. Chem. Chemother. 16 (2005) 295-302
14. Bethell R.C., Parkin N., and Lie Y. Antiviral activity of SPD-754 against clinical isolates of HIV-1 resistant to other nucleoside reverse transcriptase inhibitors. Proceedings of the XII International HIV Drug Resistant workshop. Cabo del Sol, Los Cabos, Mexico (2003)
15. Bridges E.G., Jiang Z., and Cheng Y.C. Characterization of a dCTP transport activity reconstituted from human mitochondria. J. Biol. Chem. 274 (1999) 4620-4625
16. Bridges E.G., Trentesaux C., Lahlil R., Spiga M.G., Jeannesson P., and Sommadossi J.P. 3′-Azido-3′-deoxythymidine inhibits erythroid-specific transcription factors in human erythroid K562 leukemia cells. Eur. J. Haematol. 56 (1996) 62-67
17. Burger D.M., Meenhorst P.L., ten Napel C.H., Mulder J.W., Neef C., Koks C.H., Bult A., and Beijnen J.H. Pharmacokinetics variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 8 (1994) 1683-1689
18. Cannard B., Sarfati S.R., and Richardson C.C. Enhance binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 273 (1998) 14596-14604
19. Capparelli E.V., Letendre S.L., Ellis R.J., Patel P., Holland D., and McCutchan J.A. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother. 49 (2005) 2504-2506
20. Carpenter C.C., Cooper D.A., Fischl M.A., Gatell J.M., Katzenteins, Montaner J.S., Richman D.D., Saag M.S., Schechter M., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., and Volberding P.A. Antiretroviral therapy in adults: updated recommendations of the International Society-USA Panel. JAMA 19 (2000) 381-390
21. Chen C.H., and Cheng Y.C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′-dideoxycytidine. J. Biol. Chem. 267 (1992) 2856-2859
22. Chen H., Boudinot F.D., Chu C.K., McClure H.M., and Schinazi R.F. Pharmacokinetics of (-)-β-d-2-aminopurine dioxolane and (-)-β-d-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-β-d-dioxolane guanine rhesus monkeys. Antimicrob. Agents Chemother. 40 (1996) 2332-2336
23. Chen H., Schinazi R.F., Rajagopalan P., Gao Z., Chu C.K., McClure H.M., and Boudinot F.D. Pharmacokinetics of (-)-beta-d-dioxolane guanine and prodrug (-)-beta-d-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Hum. Retroviruses 15 (1999) 1625-1630
24. Cheng Y.C., and Borroto-Esoda K. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 68 (2004) 1879-1888
25. Chin R., Shaw T., Torresi J., Sozzi V., Trautwein C., Bock T., Manns M., Isom H., Furman P., and Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45 (2001) 2495-2501
26. Chu C.K., Yadav V., Chong Y.H., and Schinazi R.F. Anti-HIV activity of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine against drug resistant HIV-1 mutants and studies of its molecular mechanism. J. Med. Chem. 48 (2005) 3949-3952
27. Cohen C., Katlama C., Murphy R., Gathe J., Brinson C., Richmond G., Girad P.-M., Fessel J., Liappis A., Puglia E., Rodwick B., Nadler J., O′Brien W., Arasteh K., Otto M.J., Erickson-Viitanen S., and Levy R. Antiretroviral activity and tolerability of reverset (d-d4FC), a new fluorocytidine nucleoside analog when used in combination therapy in treatment-experienced patients: results of Phase IIb study RVT-203. Proceedings of the Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005)
28. Collier A.C., Bozzette S., Coombs R.W., Causey D.M., Schoenfeld D.A., Spector S.A., Pettinelli C.B., Davies G., Richman D.D., Leedom J.M., Kidd P., and Corey L. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323 (1990) 1015-1021
29. Collins J.M., and Unadkat J.D. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin. Pharmacokinet. 17 (1989) 1-9
30. Corbett A.H., and Rublein J.C. DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories). Curr. Opin. Investig. Drugs 2 (2001) 348-353
31. Cui L., Schinazi R.F., Gosselin G., Imbach J.-L., Chu C.K., Rando R.F., Revankar G.R., and Sommadossi J.-P. Effect of beta-enantiomeric and racemic nucleoside analogs on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem. Pharmacol. 52 (1996) 1577-1584
32. Delta Coordinating Committee, 2001. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy. HIV Med. 2, 181-188.
33. Daluge S.M., Good S.S., Faleto M.B., Miller W.H., St. Clair M.H., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., and Krenitsky T.A. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41 (1997) 1082-1093
34. Dando T.M., and Wagstaff A.J. Emtricitabine/tenofovir disoproxil fumarate. Drugs 64 (2004) 2075-2082 (discussion 2090)
35. Darque A., Valette G., Rousseau F., Wang L.H., Sommadossi J.-P., and Zhou X.-J. Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43 (1999) 2245-2250
36. Deeks S.G., Hoh R., Neilands T.B., Liegler T., Aweeka F., Petropoulos C.J., Grant R.M., and Martin J.N. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192 (2005) 1537-1544
37. DeJesus E., McCarty D., Farthing C.F., Shortino D.D., Grinsztejn B., Thomas D.A., Schrader S.R., Castillo S.A., Sension M.G., Gough K., and Madison S.J. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin. Infect. Dis. 39 (2004) 411-418
38. Dienstag J.L., Schiff E.R., Mitchell M., Casey Jr. D.E., Gitlin N., Lissoos T., Gelb L.D., Condreay L., Crowther L., Rubin M., and Brown N. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 30 (1999) 1082-1087
39. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., Crowther L., Condreay L.D., Woessner M., Rubin M., and Brown N.A. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341 (1999) 1256-1263
40. Doong S.L., Tsai C.H., Schinazi R.F., Liotta D.C., and Cheng Y.C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 8495-8499
41. Dore G.J., Cooper D.A., Barrett C., Goh L.E., Thakrar B., and Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J. Infect. Dis. 180 (1999) 607-613
42. Erickson-Viitanen S., Hou K., Lloyd R.J., Mathis R., Burns D., Goyvaerts R., and Levy R. Baseline genotype/phenotype, virological response, and lack of de novo resistance mutation generation during therapy with dexelvucitabine (formerly reverset) in study RVT-203. Proceedings of the 13th Conference on retroviruses and opportunistic infections. Denver, CO (2006)
43. Erickson-Viitanen S., Wu J.T., Shi G., Unger S., King R.W., Fish B., Klabe R., Gelenziunas R., Gallagher K., Otto M.J., and Schinazi R.F. Cellular pharmacology of D-d4FC, a nucleoside analog active against drug-resistant HIV. Antivir. Chem. Chemother. 14 (2003) 39-47
44. Eriksson B.F., Chu C.K., and Schinazi R.F. Phosphorylation of 3′-azido-2′,3′-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5′-triphosphate. Antimicrob. Agents Chemother. 33 (1989) 1729-1734
45. Eriksson S., Kierdaszuk B., Munch-Petersen B., Oberg B., and Johansson N.G. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem. Biophys. Res. Commun. 176 (1991) 586-592
46. + cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333 (1995) 1662-1669
47. Faletto M.B., Miller W.H., Garvey E.P., St. Clair M.H., Daluge S.M., and Good S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41 (1997) 1099-1107
48. Feng J.Y., Murakami E., Zorca S.M., Johnson A.A., Johnson K.A., Schinazi R.F., Furman P.A., and Anderson K.S. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. 48 (2004) 1300-1306
49. Feng J.Y., Parker W.B., Krajewski M.L., Deville-Bonne D., Veron M., Krishnan P., Cheng Y.C., and Borroto-Esoda K. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 68 (2004) 1879-1888
50. Feng J.Y., Shi J., Schinazi R.F., and Anderson K.S. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J. 13 (1999) 1511-1517
51. Fletcher C.V. Pharmacologic considerations for therapeutic success with antiviral agents. Ann. Pharmacother. 33 (1999) 989-995
52. Fletcher C.V., Brundage R.C., Remmel R.P., Page L.M., Weller D., Calles N.R., Simon C., and Kline M.W. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob. Agents Chemother. 44 (2000) 1029-1034
53. Frick L.W., Lambe C.U., St. John L., Taylor L.C., and Nelson D.J. Pharmacokinetic, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′R,5′S)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob. Agents Chemother. 38 (1994) 2722-2729
54. Frick L.W., St. John L., Taylor L.C., Painter G.R., Furman P.A., Liotta D.C., Furfine E.S., and Nelson D.J. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob. Agents Chemother. 37 (1993) 2285-2292
55. Fromenty B., and Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol. 26 Suppl. 2 (1997) 43-53
56. Furman P.A., Davis M., Liotta D.C., Paff M.T., Frick L.W., Nelson D.J., Dornsife R.E., Wurster J.A., Wilson L.J., Fyfe J.A., Tuttle J.V., Miller W.H., Condreay L., Averett D.R., Schinazi R.F., and Painter G.R. The anti-hepatitis B activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (FTC). Antimicrob. Agents Chemother. 36 (1992) 2686-2692
57. Furman P.A., Fyfe J.A., St Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., and Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8333-8337
58. Furman P.A., Jeffrey J.L., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., Hill E., Copeland W.C., Chu C.K., Sommadossi J.-P., Liberman I., Schinazi R.F., and Painter G.R. Mechanism of action of 1-β-d-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-d-dioxolane guanosine. Antimicrob. Agents Chemother. 45 (2001) 158-165
59. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., Lu B., McColl D., Chuck S., Enejosa J., Toole J.J., and Cheng A.K. Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354 (2006) 251-260
60. Gao W.-Y., Agbaria R., Driscoll J.S., and Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269 (1994) 12633-12638
61. Gitterman S.R., Drusano G.L., Egorin M.J., and Standiford H.C. Population pharmacokinetics of zidovudine. Clin. Pharmacol. Ther. 48 (1990) 161-167
62. Goedken A.M., and Herman R.A. Once-daily abacavir in place of twice daily administration. Ann. Pharmacother. 39 (2005) 1302-1308
63. Gu Z., Allard B., de Muys J.M., Lippens J., Rando R.F., Nguyen-Ba N., Ren C., McKenna P., Taylor D.L., and Bethell R.C. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50 (2006) 625-631
64. Gu Z., Wainberg M.A., Nguyen-Ba N., L'Heureux L., de Muys J.M., Bowlin T.L., and Rando R.F. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43 (1999) 2376-2382
65. Gu Z., Wainberg M.A., Nguyen-Ba P., L'Heureux L., de Muys J.M., and Rando R.F. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane. Nucleosides Nucleotides 18 (1999) 891-892
66. Gulick R.M. New antiretroviral drugs. Clin. Microbiol. Infect. 9 (2003) 186-193
67. Gulick R.M., Ribaudo H.J., Shikuma C.M., Lustgarten S., Squires K.E., Meyer W.A., and Acosta E.P. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350 (2004) 1850-1861
68. Hammer S.M., Katzenstein D.A., Hughes M.D., Gundacker H., Schooley R.T., Haubrich R.H., Henry W.K., Lederman M.M., Phair J.P., Niu M., Hirsch M.S., and Merigan T.C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cells counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335 (1996) 1081-1090
69. Havlir D.V., Tierney C., Friedland G.H., Pollard R.B., Smeaton L., Sommadossi J.-P., Fox L., Kesseler H., Fife K.H., and Richman D.D. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis. 182 (2000) 321-325
70. Hawkins T., Veikley W., St Claire R.L., Guyer B., Clark N., and Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39 (2005) 406-411
71. Hernandez-Santiago B., Rapp K.L., Mathew J., and Schinazi R.F. Lack of antagonistic interactions for the two cytidine analogs Reverset™ and Lamivudine in vitro. HIV DART 2004: Frontiers in Drug Development for Antiretroviral Therapies. Montego Bay, Jamaica (2004)
72. Hervey P.S., and Perry C.M. Abacavir. A review of its clinical potential in patients with HIV infection. Drugs 60 (2000) 447-479
73. Herzmann C., Arasteh K., Murphy R.L., Schulbin H., Kreckel P., Drauz D., Schinazi R.F., Beard A., Cartee L., and Otto M.J. Safety, pharmacokinetics, and efficacy of (±)-β-2′,3′-dideoxy-5-fluoro-3′-thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49 (2005) 2828-2833
74. Hurwitz S.J., Otto M.J., and Schinazi R.F. Comparative pharmacokinetics of racivir, (±)-beta-2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir. Chem. Chemother. 16 (2005) 117-127
75. Jeffrey J.L., Feng J.Y., Qi C.C., Anderson K.S., and Furman P.A. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. J. Biol. Chem. 278 (2003) 18971-18979
76. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., and Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276 (2001) 40847-40857
77. Johnson M.A., Moore K.H.P., Yuen G.J., Bye A., and Pakes G.E. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36 (1999) 41-66
78. Jullien V., Treluyer J.M., Chappuy H., Dimet J., Rey E., Dupin N., Salmon D., Pons G., and Urien S. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. Br. J. Clin. Pharmacol. 59 (2005) 183-188
79. Jullien V., Treluyer J.M., Rey E., Jaffray P., Krivine A., Moachon L., Lillo-Le Louet A., Lescoat A., Dupin N., Salmon D., Pons G., and Urien S. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob. Agents Chemother. 49 (2005) 3361-3366
80. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22 (2000) 685-708
81. Kearney B.P., Flaherty J.F., and Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43 (2004) 595-612
82. Kewn S., Wang L.H., Hoggard P.G., Rousseau F., Hart R., MacNeela J.P., Khoo S.H., and Back D.J. Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47 (2003) 255-261
83. Korba B.E., Schinazi R.F., Cote P., Tennant B.C., and Gerin J.L. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 44 (2000) 1757-1760
84. Kuritzkes D.R., Quinn J.B., Benoit S.L., Shugarts D.L., Griffin A., Bakhtiari M., Poticha D., Eron J.J., Fallon M.A., and Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 10 (1996) 975-981
85. Lavie A., Schlichting I., Vetter I.R., Konrad M., Reinstein J., and Goody R.S. The bottleneck in AZT activation. Nat. Med. 3 (1997) 922-924
86. Lee H., Hanes J., and Johnson K.A. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42 (2003) 14711-14719
87. Lennerstrand J., Bluemling G.R., Ruckstuhl M., Bennett M., Chu C.K., and Schinazi R.F. 1-(β-d-Dioxolane)thymine (DOT) is effective against HIV-1 containing TAMs and M184V. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO (2006)
88. Lennerstrand J., Hassani-Espili N., Pavlova A., Chu C.K., Asif G., and Schinazi R.F. Mechanism of HIV-1 reverse transcriptase resistance to β-d-dioxolane-guanine triphosphate. Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2005)
89. Lewis W., Kohler J.J., Hosseini S.H., Haase C.P., Copeland W.C., Bienstock R.J., Ludaway T., McNaught J., Russ R., Stuart T., and Santoianni R. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20 (2006) 675-684
90. Lipsky J.J. Antiretroviral drugs for AIDS. Lancet 348 (1996) 800-803
91. Lorenzi P., Yerly S., Abderrakim K., Fathi M., Rutschmann O.T., von Overbeck J., Leduc D., Perrin L., and Hirschel B. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 11 (1997) F95-F99
92. Louie M., Hogan C., Hurley A., Simon V., Chung C., Padte N., Lamy P., Flaherty J., Coakley D., Di Mascio M., Perelson A.S., and Markowitz M. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 17 (2003) 1151-1156
93. Lyseng-Williamson K.A., Reynolds N.A., and Plosker G.L. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 65 (2005) 413-432
94. Manouilov K.K., Manouilova L.S., Boudinot D.F., Schinazi R.F., and Chu C.K. Biotransformation and pharmacokinetics of prodrug 9-(β-d-1,3-dioxolan-4-yl)guanine in mice. Antivir. Res. 35 (1997) 187-193
95. Margolis D., Mukherjee L., Hogg E., Fletcher C., Ogata-Arakaki D., Petersen T., Rusin D., Martinez A., Adams E., Mellors J., and team A. A phase I/II randomised, double-blind, placebo-controlled pilot study of β-d-2 6-diaminopurine dioxolane versus DAPD + mycophenolate mofetil in treatment-experienced subjects (ACTG 5165). Proceedings of the 13th Conference on retroviruses and opportunistic infections. Denver, CO (2006)
96. Martin A.M., Hammond E., Nolan D., Pace C., Den Boer M., Taylor L., Moore H., Martinez O.P., Christiansen F.T., and Mallal S. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am. J. Hum. Genet. 72 (2003) 549-560 (Erratum in: Am. J. Hum. Genet. 2003, 2072, 1358)
97. McKee E.E., Bentley A.T., Hatch M., Gingerich J., and Susan-Resiga D. Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc. Toxicol. 4 (2004) 155-167
98. Mewshaw J.P., Myrick F.T., Wakefield D.A., Hooper B.J., Harris J.L., McCreedy B., and Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J. Acquir. Immune Defic. Syndr. 29 (2002) 11-20
99. Miller V., Stark T., Loeliger A.E., and Lange J.M. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 3 (2002) 135-145
100. Molina J.M., Peytavin G., Perusat S., Lascoux-Combes C., Serein D., Rozebaum W., and Chene G. Pharmacokinetics of emtricitabine, didanosine and efavirenz administrated once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 5 (2004) 99-104
101. Moore K.H., Yuen G.J., Hussey E.K., Pakes G.E., Eron J.J.J., and Bartlett J.A. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob. Agents Chemother. 43 (1999) 3025-3029
102. Moore K.H.P., Barrett J.E., Shaw S., Pakes G.E., Churchus R., Kapoor A., Lloyd J., Barry M.G., and Back D. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13 (1999) 2239-2250
103. Moore L.F., Ascenzi M.A., Tennant B.C., Shi J., Schinazi R.F., and Boudinot F.D. Stereoselective Pharmacokinetics and Metabolism of 2′-Deoxy-Fluoro-3′-Thiacytidine (FTC) in Woodchucks (1997), American Association Scientist (AAPS), Boston, Mass, USA
104. Morse G.D., Lechner J.L., Santora J.A., and Rozek S.L. Zidovudine update: 1990. DICP 24 (1990) 754-760
105. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 22 (2000) 911-936 (discussion 898)
106. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir. Ther. 10 Suppl. 2 (2005) M47-M52
107. Murakami E., Ray A.S., Schinazi R.F., and Anderson K.S. Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. Antivir. Res. 62 (2004) 57-64
108. Nijhuis M., Schuurman R., de Jong D., van Leeuwen R., Lange J., Danner S., Keulen W., de Groot T., and Boucher C.A. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J. Infect. Dis. 176 (1997) 398-405
109. Otto M.J. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr. Opin. Pharmacol. 4 (2004) 431-436
110. Pereira C.F., and Paridaen J.T. Anti-HIV drug development-an overview. Curr. Pharm. Des. 10 (2004) 4005-4037
111. Piliero P.J. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 37 Suppl. 1 (2004) S2-S12
112. Ray A.S., Murakami E., Peterson C.N., Shi J., Schinazi R.F., and Anderson K.S. Interactions of enantiomers of 2′,3′-didehydro-2′,3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antivir. Res. 56 (2002) 189-205
113. Ray A.S., Schinazi R.F., Murakami E., Bassavapathruni A., Shi J., Zorca S.M., Chu C.K., and Anderson K.S. Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antivir. Chem. Chemother. 14 (2003) 115-125
114. Reardon J.E., and Miller W.H. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5′-triphosphate and 3′-azido-3′-deoxythymidine 5′-triphosphate. J. Biol. Chem. 265 (1990) 20302-20307
115. Richman D.D., Fischl M.A., Grieco M.H., Gottlieb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Hirsch M.S., et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317 (1987) 192-197
116. Robbins B.L., Srinivas R.V., Kim C., Bischofberger N., and Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42 (1998) 612-617
117. Ruane P.J., and DeJesus E. New nucleoside/nucleotide backbone options: a review of recent studies. J. Acquir. Immune Defic. Syndr. 37 (2004) S21-S29
118. Ruane P.J., Richmond G.J., DeJesus E., Hill-Zabala C.E., Danehower S.C., Liao Q., Johnson J., and Shaefer M.S. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naive patients infected with human immunodeficiency virus. Pharmacotherapy 24 (2004) 307-312
119. Schinazi R.F. Combined therapeutic modalities for viral infections-rationale and clinical potential. In: Chou T.C., and Rideout D.C. (Eds). Synergism and antagonism in Chemotherapy (1991), Academic Press, Orlando, FL 110-181
120. Schinazi R.F., Asif G., Detorio M., Hernandez-Santiago B., Ruckstuhl M., Yadav V., Rapp K.L., Bennett M., Grier J., Xie M.-Y., Lennerstrand J., Kozlowski M., Lutz S., Hurwitz S.J., and Chu C.K. 1-(β-d-dioxolane)thymidine (DOT) is a TK-dependent orally bioavailable nucleoside with specific activity against HIV-1 resistant variants. Antivir. Ther. 10 (2005) S1-S65
121. Schinazi R.F., Boudinot F.D., Ibrahim S.S., Manning C., McClure H.M., and Liotta D.C. Pharmacokinetics and metabolism of racemic 2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rhesus monkeys. Antimicrob. Agents Chemother. 36 (1992) 2432-2438
122. Schinazi, R.F., McMillan, A., Lloyd, J.R.L., Schlueter-Wirtz, S., Liotta, D.C., Chu, C.K., 1997. Molecular properties of HIV-1 resistant to (+)-enantiomers and racemates of oxathiolane cytosine nucleoside and their potential for the treatment of HIV and HBV infections. Antivir. Res. 34, A42.
123. Schinazi R.F., Mellors J., Bazmi H., Diamond S., Garber S., Gallagher K., Gelenziunas R., Klabe R., Pierce M., Rayner M., Wu J.-T., Zhang H., Hammond J., Bacheler L., Manion D.J., Otto M.J., Stuyver L.J., Trainor G., Liotta D.C., and Erickson-Viitanen S. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrob. Agents Chemother. 46 (2002) 1394-1401
124. Schooley R.T., Ramirez-Ronda C., Lange J.M., Cooper D.A., Lavelle J., Lefkowitz L., Moore M., Larder B.A., St Claire R.L., Mulder J.W., McKinnis R., Pennington K.N., Harrigan P.R., Kinghorn I., Steel H., and Rooney J.F. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J. Infect. Dis. 173 (1996) 1354-1366
125. Seigneres B., Pichoud C., Martin P., Furman P., Trepo C., and Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36 (2002) 710-722
126. Sension M.G., Bellos N.C., Johnson J., Sepulveda G.E., DeJesus E., Santana J.L., Ames M.H., and Goodwin S.D. Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients. HIV Clin. Trials 3 (2002) 361-370
127. Sharma P.L., Nurpeisov V., Hernandez-Santiago B., Beltran T., and Schinazi R.F. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 895-921
128. Siliciano J.D., and Siliciano R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54 (2004) 6-9
129. Siliciano R.F. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top. HIV Med. 13 (2005) 96-100
130. Solas C., Li Y.F., Xie M.-Y., Sommadossi J.-P., and Zhou X.-J. Intracellular nucleotides of (-)-2′,3′-deoxy-3′-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 42 (1998) 2989-2995
131. Sommadossi J.-P. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 3 (1982) S1-S8
132. Spiga M.G., Weidner D.A., Trentesaux C., LeBoeuf R.D., and Sommadossi J.P. Inhibition of beta-globin gene expression by 3′-azido-3′-deoxythymidine in human erythroid progenitor cells. Antivir. Res. 44 (1999) 167-177
133. Staszewski S., Loveday C., Picazo J.J., Dellarnonica P., Skinhoj P., Johnson M.A., Danner S.A., Harrigan P.R., Hill A.M., Verity L., and McDale H. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 276 (1996) 111-117
134. Stein D.S., Fish D.G., Bilello J.A., Preston S.L., Martineau G.L., and Drusano G.L. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10 (1996) 485-492
135. Stuyver L., Fried M.W., Van Geyt C., Rossau R., Sablon E., and Schinazi R.F. Dynamics of emergence and disappearance of lamivudine-associated mutations in hepatitis B virus. In: Schinazi R.F., and Schiff E.R. (Eds). Framing the knowledge of therapeutics for viral hepatitis (2006), IHL Press, College Park, GA 505-515
136. Stuyver L.J., Lostia S., Adams M., Mathew J.S., Pai B.S., Grier J., Tharnish P.M., Choi Y., Chong Y., Choo H., Chu C.K., Otto M.J., and Schinazi R.F. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46 (2002) 3854-3860
137. Stuyver L.J., McBrayer T.R., Schurmann D., Kravec I., Beard A., Cartee L., Schinazi R.F., de la Rosa A., Murphy R.L., and Otto M.J. Potent antiviral effect of Reverset™ in HIV-1-infected adults following a single oral dose. Antivir. Ther. 9 (2004) 529-536
138. Suo Z., and Johnson K.A. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J. Biol. Chem. 273 (1998) 27250-27258
139. Taylor D.L., Ahmed P.S., Tyms A.S., Wood L.J., Kelly L.A., Chambers P., Clarke J., Bedard J., Bowlin T.L., and Rando R.F. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(±)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antivir. Chem. Chemother. 11 (2000) 291-301
140. Thompson M.A., Kessler H.A., Eron Jr. J.J., Jacobson J.M., Adda N., Shen G., Zong J., Harris J., Moxham C., and Rousseau F.S. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 19 (2005) 1607-1615
141. Wang L.H., Begley J., St Claire R.L., Harris J., Wakeford C., and Rousseau F.S. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res. Hum. Retroviruses 20 (2004) 1173-1182
142. Wang L.H., Chittick G.E., and McDowell J.A. Single-dose pharmacokinetics and safety of abacavir (159U89), zidovudine, and lamivudine administrated alone and in combination in adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 43 (1999) 1708-1715
143. Weidner D.A., Bridges E.G., Cretton E.M., and Sommadossi J.P. Comparative effects of 3′-azido-3′-deoxythymidine and its metabolite 3′-amino-3′-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells. Mol. Pharmacol. 41 (1992) 252-258
144. Weidner D.A., and Sommadossi J.P. 3′-Azido-3′-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells. Mol. Pharmacol. 38 (1990) 797-804
145. Weller S., Radomski K.M., Lou Y., and Stein D.S. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 44 (2000) 2052-2060
146. White K.L., Margot N.A., Ly J.K., Chen J.M., Ray A.S., Pavelko M., Wang R., McDermott M., Swaminathan S., and Miller M. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 19 (2005) 1751-1760
147. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., and Naeger L.K. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46 (2002) 3437-3446
148. Yeni P.G., Hammer S.M., Hirsch M.S., Saag M.S., Schechter M., Carpenter C.C., Fischl M.A., Gatell J.M., Gazzard B.G., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292 (2004) 251-265
149. Ying C., De Clercq E., Nicholson W., Furman P., and Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, l-FMAU, DAPD, penciclovir and lobucavir. J. Viral Hepat. 7 (2000) 161-165
150. Youle, M., NATAP.org, 2004. Studies of new pipeline drugs. HIV Treatment Bulletin 5.
151. Yuen G.J., Lou Y., Bumgarner N.F., Bishop J.P., Smith G.A., Otto V.R., and Hoelscher D.D. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 mg once daily and 150 mg twice daily. Antimicrob. Agents Chemother. 48 (2004) 176-182
152. Zapor M.J., Cozza K.L., Wynn G.H., Wortmann G.W., and Armstrong S.C. Antiretrovirals. Part II. Focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 45 (2004) 524-535
153. Zhang R., Lu Z., Diasio C.R., Liu T., and Soong S.J. The time of administration of 3′-azido-3′-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy. Antimicrob. Agents Chemother. 37 (1993) 1771-1776
154. Zhang R., Lu Z., Liu T., Soong S.J., and Diasio R.B. Circadian rhythm of rat spleen cytoplasmic thymidine kinase. Biochem. Pharmacol. 45 (1993) 1115-1119
155. Zhou X.J., Sheiner L.B., D′Aquila R.T., Hughes M.D., Hirsch M.S., Fischl M.A., Johnson V.A., Myers M., and Sommadossi J.-P. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43 (1999) 121-128